EBS.US Emergent Biosolutions Inc

Healthcare Biotechnology USA Stocks
5.79 USD
Close of Nov 14, 2026
4.36 14.06
Market cap
USD 298M
P/E
-
P/B
0.97x
ROE
-87.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EBS.US undervalued?

Graham number

The Graham number of Emergent Biosolutions Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Emergent Biosolutions Inc fundamental analysis

No fundamental analysis for Emergent Biosolutions Inc yet.

Emergent Biosolutions Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Emergent Biosolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhala…

Full company profile